-
03 August 2022
-
03 August 2022
Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer
PARIS, FRANCE, 03 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival (OS) compared to topotecan. The trial is evaluating Onivyde® (irinotecan...
-
19 April 2022
-
19 April 2022
Ipsen Sponsors Pancreatic Cancer Action Network’s Purplestride Walk
Cambridge, Massachusetts (April 19th, 2022)—Ipsen supports Pancreatic Cancer Action Network (PanCAN) as a national sponsor of the organization’s PanCAN PurpleStride, their event to end pancreatic cancer. On April 30, 60 communities acros...
-
25 January 2022
- 2 mins read
-
25 January 2022
- 2 mins read
Our pledge: summaries in plain language for all journal publications
Today, we are broadening our commitment to providing everyone with the opportunity to read and understand our research. From July 2022, we will publish, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications fr...
-
03 November 2021
-
03 November 2021
Ipsen appoints Stewart Campbell Executive Vice President and President of North America
CAMBRIDGE, Massachusetts, November 3, 2021 — Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will lead th...
-
11 March 2020
-
11 March 2020
Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy
– In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline® Depot(lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide–CAMBRIDGE, Mass. March 11, 2020 — Ipsen Biopha...
-
26 September 2019
-
26 September 2019
Ipsen Announces FDA Approval of Dysport®(abobotulinumtoxinA) for the Treatment of Upper LimbSpasticity in Children, Excluding Cerebral Palsy
– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatricupper and lower limb spasticity1 –– Pivotal Phase 3 study demonstrated Dysport improved spasticity symptoms in children agedtwo to 17 experiencing upper limb ...
-
24 June 2019
-
24 June 2019
Ipsen Announces U.S. FDA Approval for Newly DesignedPre-Filled Syringe for Somatuline® Depot (lanreotide)
– New Syringe Designed to Help Enhance Injection Experience –Cambridge, Mass., June 24, 2019 – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR:IPSEY), announced today that the United States Food and Drug Administration (FDA) has a...
-
19 June 2019
-
19 June 2019
Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service
– Ipsen officially opens North American headquarters at One Main Street and recently renovatedR&D and Global External Innovation and Partnering facilities at 650 East Kendall Street –– More than 115 employees join together to support nine local n...